TIPRANIVIR CAPSULE ON CYP450 AND P-GLYCOPROTEIN IN HEALTHY HUMANS

点击翻译按钮获取中文摘要

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Tipranavir is a newly-marketed HIV protease inhibitor that must be administered with ritonavir. Many individual drug-drug interaction studies have demonstrated its high interaction potential. The results of some of these interaction studies (in particular, those with other protease inhibitors) were surprising, and not predicted on the basis for these interactions, and will allow for a general signal of potentially important drug interactions for further exploration. Healthy male and female volunteers are selected for this study population to remove the confounding effects of background antiretroviral and other therapies and to avoid placing HIV positive patients on monotherapy which may lead to the development of resistance to other available antriretroviral drugs.